SIGA Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Minimal Q1 deliveries led to a net loss, but a strong cash position enabled a special dividend. International expansion continues with a $13M Asia Pacific order and a new MENA partnership, while long-term outlook remains positive amid ongoing government engagement.
Fiscal Year 2025
-
2025 saw $88M in product revenue, $23M net income, and a $155M cash balance with no debt. U.S. and international demand for TPOXX remains strong, with new multi-year contracts and ongoing regulatory engagement in Europe. Capital allocation remains disciplined.
-
Product revenue for the first nine months of 2025 rose to $86 million, with strong U.S. government and international sales. Cash remains robust at $172 million and no debt, supporting ongoing R&D and shareholder returns. Ongoing government engagement and pipeline progress position the company for future growth.
-
Q2 2025 saw $79 million in product revenues, strong government funding, and robust net income. Regulatory and international expansion efforts continue, with a solid cash position and no debt. EMA review and U.S. procurement timing remain key uncertainties.
-
Q1 2025 saw $6M in product revenue, strong international growth, and major U.S. government orders. Cash remains robust at $162M with no debt, and a $0.60 special dividend was declared. Regulatory and pipeline progress continues, with no tariff impact to date.
Fiscal Year 2024
-
2024 saw record product sales of $133 million, strong profitability, and expanded international reach, including new regulatory approvals and strategic partnerships. Outstanding orders of $70 million are set for 2025 delivery, and a capital management decision is expected in Q2.
-
Q3 2024 saw strong order momentum and revenue growth, with $53M in nine-month product sales and $146M in outstanding orders. Net income reached $13M for the period, and a robust cash position was maintained. New contracts, pipeline expansion, and global sales drive a positive outlook.
-
Q2 and H1 2024 revenues surged year-over-year, driven by strong U.S. and international TPOXX sales. A $113M BARDA contract option was exercised, and a special dividend was paid. Ongoing clinical trials and new international agreements support a positive outlook.